Introduction of Merck Serono Company

Merck Serono is an innovative prescription drug subsidiary of merck kgaa, which was established after Merck acquired Serono in early 2007. According to IMS Health, an authoritative market research organization, Merck Serono ranked first among the top 20 foreign-funded pharmaceutical companies in China in 2009, and has maintained a growth rate of more than 30% for three consecutive years since its establishment in 2007. Merck Serono has invested more than RMB 654.388+0.8 billion in R&D and business, and owns Merck Serono Co., Ltd. and Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd., headquartered in Beijing. Merck Serono China has more than 65,438+0.200 employees, and its business covers the whole country. At present, China has introduced 17 kinds of drugs, involving 9 fields such as tumor, reproduction, cardiovascular, thyroid, surgical emergency, neurodegeneration, growth hormone, women's health care and antiallergic. It occupies a leading position in the field of thyroid and reproduction. From 2009 to the first half of 20 10, Merck serono successfully launched six new products in China. Merck Serono combines the expertise of chemical drugs (NCE) and new biological agents (NBE) to provide innovative prescription drugs derived from chemistry and biotechnology in its key therapeutic areas. Merck Serono has comprehensive capabilities from R&D to production, marketing and sales, and operates in 65,438+050 countries around the world. Every year, R&D investment exceeds 20% of sales revenue, or about 6,543.8 billion euros, to provide patients with innovative first-class drugs. A strategic marketing team consisting of 9000 employees engaged in marketing and sales can ensure that the products cover the United States, Canada, Latin America, Europe, Asia-Pacific and Japan.